机构:[1]Department of Neonatology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.[2]Section for Learning Technology, Center for HR, Kildegårdsvej 28, 2900 Hellerup, Capital Region of Denmark, Denmark.[3]Department of Neonatology, La Paz University Hospital, Paseo de La Castellana 261, 28046 Madrid, Spain.[4]Department of Neonatology, Children’s Hospital of Fudan University, 399 Wanyuan Rd, Minhang Qu, Shanghai Shi, China.[5]Department of Neonatology, Key laboratory of Neonatal Diseases, Xiamen Children’s Hospital, 10 Zhenhai Road, Xiamen, Fujian province, China.[6]Department of Neonatology, Dehong People’s Hospital of Yunnan Province, 13 Yong Han Street, Dehong Mangshi City, Yunnan province, China.[7]Copenhagen University the department of Public Health, Section for Health Services Research, Rigshospitalet, JMC, Department of Women’s and Children’s Health, Tagensvej 22, 2200 Copenhagen, Denmark.
SafeBoosC-III is an international randomised clinical trial to evaluate the effect of treatment of extremely preterm infants during the first 3 days of life based on cerebral near-infrared spectroscopy (NIRS) monitoring versus treatment and monitoring as usual. To ensure high quality of the trial intervention as well as of patient care, we have developed a multilingual web-based training program to train relevant staff and test their competence. As we enter an under-explored area of e-learning, we have conducted a pilot study on the first of the five modules comprising the web-based training program to test the feasibility of developing such a program for an international trial with limited resources.
The module in this study focuses on the principles and practice of NIRS monitoring. The pedagogical idea was to integrate training and certification. One-hundred doctors and nurses from five Neonatal Intensive Care Units across China, Spain and Denmark were invited to participate in the pilot study. Upon completion of the NIRS module, participants were invited to evaluate their experience by completing an online survey. Data from closed-ended questions were analysed using descriptive statistics while data from open-ended questions underwent thematic analysis.
In total, 81 of 100 invited staff members entered the training module and completed the online survey. The median time and the number of questions to pass the module was 15 minutes and seven questions, respectively. Most staff found the academic level of the learning material and quiz appropriate (85% and 93% of all staff members, respectively), as well as agreeing that the module was relevant to prepare them to 'use the NIRS device' (90%). Thematic analysis revealed issues such as a discrepancy between learning material and quiz questions, lack of clarity, and technical issues.
We provide evidence of the feasibility of developing a multilingual web-based training program for an international trial, despite challenges such as low budget, language barriers and possibly differences in the clinical training of staff. Exploring the integration of training and certification for international trials, the positive results of this study motivate further developments.
ClinicalTrial.gov, NCT03770741. Registered 10 December 2018.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|4 区医学
小类|4 区医学:研究与实验
最新[2023]版:
大类|4 区医学
小类|4 区医学:研究与实验
第一作者:
第一作者机构:[1]Department of Neonatology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
通讯作者:
推荐引用方式(GB/T 7714):
Hansen Mathias Lühr,Rasmussen Marie Isabel,Rubin Snorre,et al.Pilot test of an online training module on near-infrared spectroscopy monitoring for the randomised clinical trial SafeBoosC-III.[J].Trials.2020,21(1):356.doi:10.1186/s13063-020-4206-6.
APA:
Hansen Mathias Lühr,Rasmussen Marie Isabel,Rubin Snorre,Pellicer Adelina,Cheng Guoqiang...&Greisen Gorm.(2020).Pilot test of an online training module on near-infrared spectroscopy monitoring for the randomised clinical trial SafeBoosC-III..Trials,21,(1)
MLA:
Hansen Mathias Lühr,et al."Pilot test of an online training module on near-infrared spectroscopy monitoring for the randomised clinical trial SafeBoosC-III.".Trials 21..1(2020):356